Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03258853 · ClinicalTrials.gov registry record · NA
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT03258853: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03258853 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03258853, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children with cystic fibrosis related diabetes.
Interventions
- OTHER Usual Care
- DEVICE Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2022-06-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03258853
The ClinicalTrials.gov registry entry for NCT03258853 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03258853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03258853 about?
NCT03258853 is a clinical study titled "Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes". The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children with cystic fibrosis related diabetes.
What is the current status of trial NCT03258853?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2021-08-26. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT03258853?
The interventions under investigation include: Usual Care (OTHER), Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT03258853?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.